Sunshine Biopharma Inc. SBFM
Sunshine Biopharma Inc. (Nasdaq: SBFM) is an oncology specialty pharmaceutical company. Its next catalyst on record is Nora Pharma generics (Canada): Launch of 12 additional generic drugs in Canada (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Nora Pharma generics (Canada) — Launch of 12 additional generic drugs in Canada (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| K1.1 mRNA-LNP | Liver cancer | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| SBFM-PL4 (coronavirus PLpro/Mpro protease inhibitor) | SARS-CoV-2 / betacoronavirus infection | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.